Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience Corporation (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) announced a new four-year supply agreement, enhancing their collaboration in synthetic biology. This agreement marks an increase in Ginkgo's commitments to purchase synthetic DNA from Twist to support its growth across various industries, including vaccine manufacturing and agriculture. The partnership builds on a previous agreement from 2017, highlighting a significant order of approximately one billion base pairs of synthetic DNA.
Twist Bioscience Corporation (NASDAQ: TWST) has launched synthetic RNA positive controls for SARS-CoV-2, encapsulated in proprietary stainless steel minicapsules from Imagene SA. These minicapsules provide a stable, cost-effective solution for shipping and storing fragile RNA at room temperature, overcoming cold chain limitations. This product aims to facilitate COVID-19 monitoring in regions lacking adequate storage facilities. The launch builds on a 2019 partnership with Imagene, enhancing Twist's capabilities in supplying stable RNA and DNA products globally.
Summary not available.
Twist Bioscience (NASDAQ: TWST) has entered into an antibody discovery agreement with Kriya Therapeutics, focusing on delivering antibodies via adeno-associated viral gene therapy for oncology applications. This partnership aims to leverage Twist's advanced antibody libraries and Kriya's vector engineering platform. The collaboration seeks to enhance the precision of antibody delivery for cancer treatment and potentially expedite the development of novel gene therapies, thereby providing therapeutic benefits where they are most needed.
Twist Bioscience (NASDAQ: TWST) has joined the Digital Preservation Coalition’s Supporter Program, facilitating collaboration between members on digital content preservation. This program emphasizes the importance of long-term digital data storage solutions. CEO Emily M. Leproust expressed enthusiasm for engaging with members to refine their Century Archive DNA data storage solution. The DPC aims to address challenges faced by organizations storing valuable digital assets. This partnership may enhance Twist's position in the emerging DNA data storage market.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience (NASDAQ: TWST) announced that CEO Emily M. Leproust, Ph.D., will present at several upcoming virtual investor conferences. These include the Truist Securities AI Symposium on March 1 at 9:00 a.m. ET and the Cowen 42nd Annual Health Care Conference on March 7, featuring a fireside chat at 2:10 p.m. ET and a Synthetic Biology Enabling Technologies Panel at 10:30 a.m. ET. The Cowen presentations will be webcast live, with replays available for 30 days post-event. Twist specializes in high-quality synthetic DNA products and applications across various industries.
Twist Bioscience Corporation (NASDAQ: TWST) has completed its upsized public offering of 5,227,272 shares at $55.00 each, raising approximately $269.4 million after costs. This move follows the full exercise of the underwriters' option to purchase an additional 681,818 shares. The proceeds will be allocated towards expanding R&D in pharmaceutical biologics, DNA data storage, and Next-Generation Sequencing (NGS) operations, as well as general corporate purposes and strategic investments.
Twist Bioscience Corporation (NASDAQ: TWST) has priced an upsized public offering of 4,545,454 shares at $55.00 each, aiming for gross proceeds of approximately $250 million. The offering is set to close around February 15, 2022, subject to customary conditions. Proceeds will fund R&D investments, including pharmaceutical biologics drug discovery and DNA data storage, as well as scaling operations and supporting global expansion. The underwriters are granted a 30-day option to buy an additional 681,818 shares.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 8:00 a.m. Eastern Time. The event will be webcast live, accessible through the Investor Calendar on the company’s website, with a replay available for 30 days. Twist Bioscience is a leader in synthetic biology, using a unique silicon-based DNA synthesis platform to produce synthetic DNA products across various industries, including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) announced a public offering of up to $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering's completion and terms are subject to market conditions. Proceeds will fund R&D for pharmaceutical biologics and DNA data storage, expand the commercial organization, and support NGS operations. The offering is registered with the SEC under Form S-3. J.P. Morgan, Goldman Sachs, Cowen, and William Blair are acting as joint managers.